Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation

Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation

Prophylactic tranexamic acid has shown been shown to reduce maternal mortality from postpartum hemorrhage with no adverse effects, but has not been studied to reduce bleeding complications with dilation and evacuation (D&E). We propose a randomized, double-blinded, placebo-controlled pilot study to determine whether routine use of intravenous (IV) tranexamic acid will decrease the need for interventions to control bleeding at the time of D&E at 16 to 24 weeks gestation.

Inclusion Criteria:

• Requesting pregnancy termination
• Intrauterine pregnancy at 16 to 24 weeks gestation
• Participants must be willing and capable of giving informed consent and able to understand and sign written consents in English.

Exclusion Criteria:

• History of thromboembolic events (i.e. deep vein thrombosis, stroke, pulmonary embolism)